Plasma genotyping to predict treatment benefit in NSCLC patients

15th April 2016

Three studies have been presented at the European Lung Cancer Conference in Geneva that has confirmed the positive results of using plasma genotyping to predict treatment benefits in non-small-cell lung cancer (NSCLC) patients.

However, using plasma tests will not be replacing tissue biopsies, which are still more effective at determining treatments.

Although tissue biopsies are standard, 20 per cent of NSCLC patients aren't able to go through with this small procedure.

As a result, plasma is an alternative that allows medical staff to test for epidermal growth factor receptor (EGFR) mutations to work out whether or not a patient will be viable for EGFR tyrosine kinase inhibitor therapy.

Using this plasma genotyping, doctors will be able to extract circulating tumour DNA in a way that is less invasive than a biopsy.

Dr Nicola Normanno, chief of the Cell Biology and Biotherapy Unit at INT-Fondazione Pascale in Italy and author of one of the studies, said: "Further studies are required to confirm these findings and identify potential underlying biological mechanisms - the age finding in particular is interesting."

In the tests, it as found that EGFR mutation detection in plasma was much higher in patients who were aged less than 65 years old.

Posted by Edward Bartel
 

Health News is provided by Axonn Media in collaboration with Spire Healthcare. Please note that all copy above is ©Axonn Media and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:

or

Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.

or

Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...

Categories

Cancer

© Spire Healthcare Group plc (2016)